ResearcherUniversity Health NetworkActive in the last 2 years
Michael J. Allen
Matched on ORCID iD 0000-0001-5091-5995; OpenAlex author ID A5000583912. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper
Papers 5
- Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018-2022. Last author DOI 10.1002/cam4.71226↗
- Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
- Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
- hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
- Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Co-author DOI 10.1016/j.ctrv.2021.102310↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert C. Grant · 4 shared papers, 2021–2023 · strength 0.51
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Grainne Mary O'Kane · 4 shared papers, 2021–2023 · strength 0.51
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Jennifer Jane Knox · 4 shared papers, 2021–2023 · strength 0.51
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Steve Gallinger · 4 shared papers, 2021–2023 · strength 0.51
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Faiyaz Notta · 4 shared papers, 2021–2023 · strength 0.51
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Sandra Elisabeth Fischer · 3 shared papers, 2022–2023 · strength 0.39
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- Ravi Ramjeesingh · 3 shared papers, 2021–2023 · strength 0.37
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- George Zogopoulos · 3 shared papers, 2021–2023 · strength 0.37
- Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
- Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- Danny R. Youlden · 1 shared paper, 2025 · strength 0.33
- Sheron Perera · 2 shared papers, 2022–2023 · strength 0.26
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- Mustapha Ali Tehfe · 2 shared papers, 2022–2023 · strength 0.25
- James Biagi · 2 shared papers, 2022–2023 · strength 0.25
- Yifan Wang · 2 shared papers, 2022–2023 · strength 0.25
- Rama Khokha · 1 shared paper, 2023 · strength 0.13
- Barbara T. Grünwald · 1 shared paper, 2023 · strength 0.13
- Lucy Xiaolu Ma · 1 shared paper, 2023 · strength 0.13
- Nicholas Meti · 1 shared paper, 2021 · strength 0.12
- Eitan Amir · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.